Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2027-08-07
Target enrollment:
Participant gender:
Summary
This is a phase II study to evaluate efficacy of Acalabrutinib as a maintenance therapy
following blood or marrow transplant (BMT) in patients who have been diagnosed with mantle
cell lymphoma.